Onconetix effects 1:40 reverse stock split; Nasdaq delisting notice resolved via new listing approval

Onconetix, Inc.

Reverse stock split at ratio 1:40 effective Sept. 24, 2024; no fractional shares issued, cash paid in lieu.
Nasdaq delisting notice for bid price non-compliance received Sept. 18; mooted by Sept. 19 approval of new listing application meeting $4 closing bid price.
Issued 142,749 shares to Veru upon conversion of Series A Preferred; 6,741,820 shares to former Proteomedix holders on Series B automatic conversion.
Issued 513,424 units (share + warrant) to Altos plus 154,027 shares on warrant exercise; all exempt from registration.
Post-split shares outstanding: 8,307,051 total (including 2,656 unvested restricted stock).

item 3.01 item 3.02 item 3.03 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.